AOD-9604 vs Semaglutide
Weight LossAOD-9604 and semaglutide take fundamentally different approaches to weight loss. Semaglutide is an FDA-approved GLP-1 agonist that reduces appetite and slows gastric emptying, producing dramatic weight loss (~15%). AOD-9604 is a GH fragment that targets fat metabolism directly — promoting lipolysis and inhibiting lipogenesis — without affecting appetite. Semaglutide has overwhelming clinical evidence; AOD-9604 failed to show significant weight loss in clinical trials despite a favorable side effect profile.
Side-by-Side Comparison
| Aspect | AOD-9604 | Semaglutide |
|---|---|---|
| cost | Lower — research peptide pricing | ~$900-1,350/month without insurance |
| dosing | 250-500 mcg SubQ daily on empty stomach | 0.25-2.4 mg SubQ weekly (titrated over 16-20 weeks) |
| best for | Mild fat metabolism support with minimal side effects, those who cannot tolerate GLP-1 GI effects | Significant weight loss, type 2 diabetes, cardiovascular risk reduction |
| mechanism | Growth hormone fragment — stimulates lipolysis and inhibits lipogenesis in adipose tissue without affecting blood sugar | GLP-1 receptor agonist — suppresses appetite, slows gastric emptying, enhances insulin secretion |
| fda status | Not FDA-approved; research peptide | FDA-approved: Ozempic (diabetes), Wegovy (weight loss) |
| weight loss | Modest — failed to show significant weight loss vs placebo in clinical trials | ~15% body weight in STEP trials (68 weeks) |
| side effects | Minimal — injection site reactions, rarely any GI effects | Nausea (44%), diarrhea, vomiting, constipation, possible pancreatitis risk |
Verdict
Semaglutide is far more effective for weight loss with robust clinical evidence. AOD-9604 is milder with fewer side effects but lacks proven efficacy. They can theoretically be combined — semaglutide for appetite, AOD-9604 for additional fat metabolism support.